The Emmes Group
The Emmes Group is an 18 year old consulting firm with offices in Boston and San Francisco. The Emmes Group is a strategic business development, assessment and planning organization specializing in the support of firms engaged in the technology, internet, biotechnology and pharmaceutical industries. Our partners have over 50 years of combined experience in serving technology, internet and healthcare companies. Our client list is an impressive list of some of the leading companies in the world. Good strategy depends critically on knowing root causes. Asking why helps to uncover root causes and takes strategy formulation away from the unconscious repetition of past patterns and mimicry of competitors. Asking why is a qualitative act. It is different from quantitative analysis, but one gains power from the other. It propels analysis forward by raising new questions to be subjected to rigorous analysis. It takes us beyond the numbers to new answers, new solutions, and new opportunities. It can call into question individuals diligence and the basis of their expertise. But it forces fresh thinking on all sides. Asking why leads to new
insights that often yield important competitive advantages. Having the Emmes Group as your partner can help to extend your capabilities, shorten your time frames and increase your probabilities for success. Whether you seek strategic assistance, a new business alliance or to find new markets for existing products or new products for existing markets:
*We can assist you in identifying potential strategic partners, formulating an effective
corporate development strategy or implementing a successful partnership plan.
*We can help you compile detailed strategic profiles and well deliver in-depth analyses of
your competitors (or your own) strengths and weaknesses.
*To guide your R&D activities, well help you prioritize customers or potential strategic
partners most critical needs and determine the potential of various applications.
*Well help you identify opportunities and evaluate synergistic candidates for acquisition.